Sign in to fuzzto save your conversations, follow your research and come back anytime.
Alivus Life Sciences
ALIVUS
NSE
BSE
NSEBSESectorHealthcare
1,418.80
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Alivus Life Sciences expands margins and builds cash reserves as revenue mix shifts toward non-GPL products.
EBITDA margin expands from 30.1% in Q1 FY26 to 36.6% in Q1 FY27, reflecting improved pricing and cost efficiency.
GPL revenue falls from ₹1,526 Cr in Q1 FY26 to ₹723 Cr in Q1 FY27, reducing the contribution from generic products.
Cash reserves grow from ₹6,604 Cr in Q1 FY26 to ₹8,802 Cr in Q1 FY27, strengthening the company's liquidity position.
Free cash flow drops from ₹2,590 Cr in Q4 FY26 to ₹901 Cr in Q1 FY27, indicating higher working capital requirements.
Non-GPL revenue rises from ₹4,492 Cr in Q1 FY26 to ₹5,681 Cr in Q1 FY27, driving the shift in product mix.
Non-GPL share of revenue surges from 74.6% in Q1 FY26 to 88.7% in Q1 FY27, increasing concentration in this segment.
Return on invested capital improves from 28% in Q1 FY26 to 32% in Q1 FY27, showing better returns on deployed capital.
Depreciation and amortization rises from ₹171 Cr in Q1 FY26 to ₹206 Cr in Q1 FY27, reflecting ongoing capacity investments.
Validated products increase from 9 in Q1 FY26 to 13 in Q1 FY27, accelerating the commercial pipeline.
